ARROW: Phase I Trial of BLU-667, a Novel RET Inhibitor, in Patients With Advanced RET Fusion–Positive NSCLC

May 31 - June 4, 2019; Chicago, Illinois
BLU-667, a selective and potent RET inhibitor, achieved a high response rate with durable responses in patients with RET+ NSCLC regardless of prior treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 190 KB
Released: June 4, 2019


Provided by the USF Health

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Blueprint Medicines

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Professor Keith M. Kerr on fine points of testing for EGFR exon 20 insertion mutations in management of advanced NSCLC, commentary from Clinical Care Options (CCO)

person default Keith M. Kerr, MB ChB, FRCPath, FRCPE Released: August 5, 2021

David Planchard, MD, PhD, discusses barriers to osimertinib access worldwide and future directions for the management of advanced EGFR-mutated NSCLC.

David Planchard, MD, PhD Released: July 29, 2021

On-demand webcast from a live CCO webinar capturing global perspectives from Drs. Edward S. Kim and Luis Paz-Ares on the optimal management of patients with EGFR+ NSCLC

Edward S. Kim, MD, FACP, FASCO Luis Paz-Ares, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: July 29, 2021 Expired: July 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.